The U.S. Advisory Committee on Immunization Practices recommended in 2010 that the 7-valent pneumococcal conjugate vaccine (PCV7) be replaced by the 13-valent version (PCV13), which carries a higher price. Because this higher price may be a concern for funding agencies and payers, researchers estimated the budgetary impact of the routine use of PCV13 instead of PCV7 from 2010 to 2019. Use of the PCV13 vaccine could cost public and private payers $3.5 billion and $2.6 billion, respectively, more than PCV7. However, the researchers found that the newer vaccine also is expected to provide net cost savings of $6.1 billion and $4.2 billion, respectively, to those payers during that period by preventing pneumococcal disease and its associated costs. There would be another $1.7 billion in cost savings realized for uninsured patients.